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Objective: Over the past 20 years, the incidence of endometrial cancer has increased remarkably 
in Japan. The number of elderly females has also increased within the population of Japan. We 
examined the impact of advanced age on the demographic and clinicopathological characteristics 
in Japanese patients with endometrial cancer.
Methods: Data were collected from 319 surgically treated Japanese females with endometrial 
cancer from the files of the University Hospital of Occupational and Environmental Health, 
Yahatanishi-ku, Kitakyushu, Japan, between 1990 and 2010. χ2 tests were performed to evaluate 
the trends in the variables between two decades (A: 116 cases from 1990–2000) and (B: 203 cases 
in 2001–2010). The histological subtypes were also evaluated based on the immunohistochemical 
expressions of p53, estrogen receptor, and Ki-67.
Results: The mean ages ± standard deviation in the decade A group and the decade B group 
were 57.5 years ± 9.7 years and 61.0 years ± 11.3 years, respectively (P , 0.02). There was an 
increase in the proportion of patients aged 70 years or older and of high-risk histological tumors 
including serous carcinoma, clear cell carcinoma, and carcinosarcoma (decade A group and 
decade B group: 9.5% vs 27.6%, P , 0.001, 10.4% vs 21.6%, P = 0.01, respectively), while the 
advanced surgical stage (III and IV), obesity ($25 of body mass index), and nulliparity of the 
decade A group and decade B group were 23.3% vs 29.1%, P = 0.30, 28.4% vs 33.0%, P = 0.40, 
and 19.0% vs 21.2%, P = 0.66, respectively. The cancer-specific survival rates in the decade A 
group and the decade B group were 78.6% and 77.6%, respectively (P = 0.93).
Conclusion: The increase in number of elderly females in the Japanese population is related to 
the increase in that of high-risk endometrial cancers. A study is needed to investigate prevention 
strategies and to improve the treatment of elderly patients with high-risk endometrial cancer.
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Introduction
Endometrial cancer is now the most common gynecologic malignancy in the US, with 
an estimated 43,470 new cases in 2010 and 7950 deaths.1 The number of deaths per 
year has been increasing despite a relatively stable number of new cases.2 According 
to the Gynecologic Tumor Committee of the Japan Society of Gynecologic Oncology 
(JSOG), the total number of endometrial cancer cases from registered institutions was 
976 cases in 1983, which increased to 2115 cases in 1994 and reached 6113 cases 
in 2009.3 The age-adjusted incidence rate of endometrial cancer in Japan was 3.9 in 
1990, 5.1 in 2000, and 7.6 in 2006.4 The incidence of endometrial cancer has therefore 
increased remarkably in Japan.
Advanced age is well recognized as an adverse prognostic factor in patients with 
endometrial cancer,5 and was reported to be associated with aggressive histological 
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subtypes of tumors, increased tumor grades, and advanced-
stage disease.6 In addition, elderly females with endometrial 
cancer are suggested to receive less aggressive treatment than 
their younger counterparts.7
In the present study, we determined the histological subtypes 
of endometrial cancer based on the immunohistochemical 
findings and tried to show the impact of the increase in the 
rate of elderly females within the Japanese population on 
the demographic and clinicopathological characteristics of 
Japanese patients with endometrial cancer.
Materials and methods
Case selection
The study included 319 Japanese patients with endometrial 
cancer who had undergone surgery at the University Hospital 
of Occupational and Environmental Health, Yahatanishi-ku, 
Kitakyushu, Japan, between 1990 and 2010. These included 
263 cases of endometrioid adenocarcinoma and 56 cases of 
nonendometrioid carcinoma (30 cases of serous carcinoma, 
eight cases of clear cell carcinoma, and 18 cases of 
carcinosarcoma). The demographic, clinicopathological, 
treatment, and survival information of Japanese patients 
with endometrial cancer was compared for two decades 
(A: 1990–2000, 116 cases, and B: 2001–2010, 203 cases). 
All of the studied endometrial cancer specimens were from 
hysterectomy specimens. A simple total hysterectomy in 
the decade A group and the decade B group was performed 
in 81 and 142 patients, an extended hysterectomy (class II) 
in 33 and 58 patients, and a radical hysterectomy (class III) 
in two and three patients, respectively (decade A group 
vs decade B group, P = 0.98).8 When surgeons found a 
tumor with deep myometrial invasion during the operation, 
an extended hysterectomy was performed. Radical 
hysterectomy was performed if the tumor showed a gross 
cervical involvement. A pelvic lymphadenectomy and a 
para-aortic lymph node sampling in the decade A group 
and the decade B group were performed in 99 and 170 
patients (P = 0.24), and in 39 and 103 patients (P , 0.01), 
respectively. The adjuvant chemotherapy was performed 
when patients exhibited tumor stage IB or above, grade 3 
endometrioid tumor, nonendometrioid tumor, or positive 
lymph-vascular space invasion. The adjuvant radiotherapy 
was additionally performed for the metastatic lymph nodes. 
During the period of this study, 15 patients with endometrial 
carcinoma were treated with primary radiotherapy due to 
severe complications. These 15 patients were not included in 
the present study because of little pathologic information of 
endometrial cancer. In four patients of the decade A group, 
the mean age ± standard deviation (SD) was 81.5 years ± 
5.8 years. Clinical stages I and IV tumors were seen in three 
patients and one patient, respectively. In eleven patients in 
the decade B group, the mean age ± SD was 69.1years ± 
12.2 years. Clinical stages I, II, and IV tumors were seen in 
six, two, and three patients, respectively. Tamoxifen-related 
endometrial cancer was found in three females with breast 
cancer (two endometrioid adenocarcinomas and a serous 
carcinoma).
Immunohistochemistry
For the immunohistochemical analysis, 4 µm sections were 
cut from formalin-fixed paraffin-embedded tissue blocks, 
deparaffinized in xylene, and rehydrated through sequential 
changes of alcohol and distilled water. Ki-67 and p53 were 
detected using the ready-to-use monoclonal antibodies 
against Ki-67 and p53 (clone MIB-1 and DO-7; Dako Co, 
Ltd, Kyoto, Japan), respectively. The estrogen receptor α 
(ERα) was detected using monoclonal antibodies against 
the ER (clone 6F11, diluted 1:50, Novocastra, Fukuoka, 
Japan). The slides were heated in an autoclave at 120°C 
for 5 minutes in 0.01 M citrate buffer (pH = 6.0) before 
the immunostaining. The slides were then incubated with 
indicated antibodies for 2 hours at room temperature. 
Antibody binding was visualized using the EnVision +   
Dual Link system, and diaminobenzidine was used as a 
chromogen (Dako Cytomation, Kyoto, Japan). The slides 
were counterstained with methyl green and mounted.
Interpretation of immunohistochemical 
preparations
The immunostained slides were analyzed independently by 
two authors. Slight differences were resolved by simultaneous 
viewing. The pathologic review was performed in a blinded 
fashion on all patients. The labeling indices (LIs) of KI-67, 
p53, and ER were defined as the percentage of the tumor 
cells with strong nuclear immunoreactivity out of the total 
number of the tumor cells, respectively.
Statistical analysis
The statistical analyses were carried out using the SPSS 
software program for Windows, version 18.0.0 (SPSS, 
Chicago, IL). The outcome data collected included the 
time from first surgery to the last follow-up or death. 
Kaplan–Meier curves were generated to examine the overall 
and cancer-specific survival rates. The log-rank test was 
used to test differences in survival within variables. The 
Cox proportional hazards model was used to identify and 
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simultaneously evaluate any independent prognostic factors 
associated with relative survival. The frequency distributions 
between categorical variables were compared using the χ2 
test. The mean ages of the patients were added to assessment 
by Student’s t-test. Statistical significance was considered to 
exist at a value of P , 0.05.
Results
Clinicopathologic features
In the overall study group, the mean ages ± SD of the patients 
with endometrioid adenocarcinoma, serous carcinoma, 
clear cell carcinoma, and carcinosarcoma were 57.8 years ± 
10.3 years, 69.3 years ± 7.7 years, 69.6 years ± 9.3 years, 
and 68.3 years ± 9.9 years, respectively.
We divided the study group into two time periods, 1990–
2000 (decade A group) and 2001–2010 (decade B group), to 
identify the trends in demographic and clinical characteristics 
(Table 1). The mean ages ± SD in the decade A group 
and the decade B group were 57.5 years ± 9.7 years and 
61.0 years ± 11.3 years, respectively (P , 0.02). For patients 
with high-risk histologic tumor, the mean ages ± SD in the 
decade A group and the decade B group were 67.3 years ± 
8.4 years and 69.6 years ± 8.5 years, respectively (P = 0.37). 
The cutoff point of 70 years of age showed significant 
difference between age distributions of the decade A 
group and the decade B group (P , 0.001), but those aged 
50 years and 60 years showed no significant difference 
(P = 0.08 and P = 0.34, respectively). The numbers of patients 
aged 70 years or older with high-risk histologic tumor in 
the decade A group and the decade B group were three and 
24, respectively. Between the two periods, the proportion 
of patients aged 70 years or older increased from 9.5% to 
27.6% (P , 0.001), while the rates of patients with high-risk 
histologic tumor in the decade A group and the decade B 
group were 27.3% and 42.9% for patients aged 70 years or 
older, respectively (P = 0.93). For patients aged less than 
70 years, the rates of patients with high-risk histologic tumor 
in the decade A group and the decade B group were 8.6% 
and 13.6%, respectively (P = 0.22). There was a significant 
decrease in the proportion of endometrioid adenocarcinomas 
with a corresponding increase in the nonendometrioid 
adenocarcinomas including serous carcinoma, clear cell 
carcinoma, and carcinosarcoma (P = 0.01). Compared with 
grade 1 and 2 tumors, the proportion of grade 3 tumors did not 
change significantly (P = 0.09). Nulliparity, obesity, surgical 
stage, and myometrial invasion did not change significantly 
between the decade A group and the decade B group 
(P = 0.66, 0.40, 0.30, and 0.59, respectively). The rates of 
para-aortic lymph node sampling and adjuvant chemotherapy 
increased significantly from 33.6% to 50.7% (P , 0.01) 
and from 33.6% to 43.8% (P = 0.04), respectively, from 
the decade A group to the decade B group. The presence 
of lymph node metastasis was found in 15 cases (12.9%) in 
the decade A group and 27 cases (13.3%) in the decade B 
group (P = 0.88).
Immunohistochemical findings
The histological subtypes of endometrial carcinoma were 
diagnosed by hematoxylin and eosin-stained sections. 
Although we evaluated the histological subtype of endometrial 
carcinoma using p53, Ki-67,and ER immunohistochemical 
expressions after the review of hematoxylin and eosin-stained 
slides, the histological subtypes of endometrial carcinoma 
were not changed by the immunophenotypes of the tumors 
except for one tumor (which changed in classification from 
serous carcinoma to endometrioid adenocarcinoma due to the 
absence of p53 and a high level of expression of the ER).
In the overall study group, the cases showing more 
than 50% of LIs for p53 was 41 of 263 endometrioid 
adenocarcinomas (11.6% of grade 1 tumors, 18.2% of grade 
2 tumors, and 28.2% of grade 3 tumors), 29 of 30 serous 
carcinomas, eight of eight clear cell adenocarcinomas, 
and 13 of 18 carcinosarcomas. The samples showing more 
than 10% of LIs for ER were 77 of 263 endometrioid 
adenocarcinomas (81.0% of grade 1 tumors, 73.7% of grade 
2 tumors, and 32.2% of grade 3 tumors), eight of 30 serous 
carcinomas, none of eight clear cell adenocarcinomas, and 
three of 18 carcinosarcomas. The samples showing more 
than 50% of LIs for Ki-67 were 166 of 263 endometrioid 
adenocarcinomas (54.4% of grade 1 tumors, 72.7% of grade 
2 tumors, and 76.9% of grade 3 tumors), 28 of 30 serous 
carcinomas, seven of eight clear cell adenocarcinomas, and 
17 of 18 carcinosarcomas.
Survival rates
Figure 1 shows that the decade A group and the decade 
B group had follow-up periods ranging from 3 months to 
221 months (median 82 months) with a cancer-specific 
survival rate of 78.6% and follow-up periods ranging 
from 2 months to 128 months (median 45 months) with 
a cancer-specific survival rate of 77.6%, respectively 
(P = 0.93). The cancer-specific survival rates of patients 
with endometrioid adenocarcinoma (grades 1, 2, and 3), 
serous carcinoma, clear cell carcinoma, and carcinosarcoma 
were 96.8%, 75.3%, 65.6%, 46.2%, 45.2%, and 11.8%, 
respectively (P , 0.0001). The overall survival rates of 
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patients with endometrioid adenocarcinoma (grades 1, 
2, and 3), serous carcinoma, clear cell carcinoma, and 
carcinosarcoma were 94.6%, 68.8%, 64.5%, 44.1%, 
36.6%, and 9.7%, respectively (P , 0.0001). The cancer-
specific survival rates of patients with endometrioid tumor 
and nonendometrioid tumor were 86.2% and 37.2%, 
respectively (P , 0.001).
On multivariate analyses including variables of age at 
diagnosis (aged ,70 years vs aged 70 years or older), surgical 
stage (I and II vs III and IV), histology (endometrioid tumors 
vs nonendometrioid tumors), and p53 expression (,50% 
of LI vs 50% or more of LIs), surgical stage (hazard ratio 
[HR] = 2.939, 95% confidence interval [CI] = 5.268–67.738, 
P-value , 0.001) was a significant independent prognostic 
factor in the decade A group. Age of diagnosis (HR = 0.948, 
95% CI = 1.050–6.349, P-value = 0.039), surgical stage 
(HR = 1.734, 95% CI = 2.149–14.937, P-value , 0.001), 
and histology (HR = 2.506, 95% CI = 3.307–45.455, 
P-value , 0.001) were significant independent prognostic 
factors in the decade B group.
Table 1 Demographic, clinicopathologic, and treatment trends
Characteristics Decade A group 
(n = 116) (%)a
Decade B group 
(n = 203) (%)a
P-value
Age (year) <0.001
  ,70 105 (90.5) 147 (72.4)
  $70 11 (9.5) 56 (27.6)
Parity 0.66
 0 22 (19.0) 43 (21.2)
  1–2 62 (53.4) 113 (55.7)
  $3 32 (27.6) 47 (23.1)
Body mass index 0.40
  ,25 83 (71.6) 136 (67.0)
  $25 33 (28.4) 67 (33.0)
Pelvic lymphadenectomy 99 (85.3) 170 (83.7) 0.24
Para-aortic lymph node sampling 39 (33.6) 103 (50.7) ,0.01
Median number of nodes (range)
  Pelvic 14 (1–40) 13 (1–47)
  Para-aortic 1 (1–7) 1 (1–14)
Positive lymph nodeb 0.88
  Pelvic 12 (10.3) 12 (5.9)
  Para-aortic 2 (1.7) 4 (2.0)
  Pelvic and para-aortic 1 (0.9) 11 (5.4)
Surgical stagec 0.30
  IA 71 (61.2) 109 (53.7)
  IB 14 (12.1) 24 (11.8)
  II 4 (3.4) 11 (5.4)
  IIIA 7 (6.0) 19 (9.4)
  IIIB 1 (0.9) 2 (1.0)
  IIIC1 9 (7.8) 12 (5.9)
  IIIC2 4 (3.4) 11 (5.4)
  IV 6 (5.2) 15 (7.4)
Myometrial invasion  0.59
 , 1/2 80 (69.0) 134 (66.0)
 $ 1/2 36 (31.0) 69 (34.0)
Histologyd 0.01
  Endometrioid
    Grade 1 59 (50.8) 88 (43.4)
    Grade 2 32 (27.6) 45 (22.2)
    Grade 3 13 (11.2) 26 (12.8)
    Serous 6 (5.2) 24 (11.8)
    Clear cell 1 (0.9) 7 (3.4)
    Carcinosarcoma 5 (4.3) 13 (6.4)
Adjuvant chemotherapy 39 (33.6) 89 (43.8) 0.04
Adjuvant radiotherapy 5 (4.3) 7 (3.4) 0.70
Notes: aPercent denotes proportion of patients during decade; bcases with lymph node metastasis versus cases without lymph node metastasis; cstages I and II versus stages III 
and IV; dendometrioid versus serous carcinoma, clear cell carcinoma, and carcinosarcoma.
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Discussion
In the present study, the incidence of high-risk histological 
tumors including serous carcinoma, clear cell carcinoma, 
and carcinosarcoma was significantly increased, and these 
cancers were seen most in elderly patients. The incidences of 
obese or nulliparous patients were not significantly different 
between the decade A group and the decade B group.
The Surveillance, Epidemiology and End Results (SEER) 
database of the National Cancer Institute between 1988 
and 2001 showed that the incidence of endometrial cancer 
remained relatively stable in the US, while the number of 
deaths per year was estimated at an approximate 3000 in 
the 1980s, 5000 in the 1990s, and over 7000 in 2006. This 
increased number of deaths was suggested to be partially 
related to an increased rate of detection of advanced-stage 
(III and IV) cancer (14.2% of 13,591 patients in 1988–
1992 vs 18.0% of 15,979 patients in 1998–2001, P , 0.001) 
and high-risk histologies, including serous carcinoma, clear 
cell carcinoma, and sarcoma (14.7% of 13,591 patients 
in 1988–1992 vs 17.3% of 15,979 patients in 1998–2001, 
P , 0.001).2
On the contrary, the analyses of endometrial cancer 
histological subtypes, based on the database of the National 
Program of Cancer Registries (NPCR) and SEER programs 
between 1999 and 2006, showed that the incidence of 
type I endometrial cancers (endometrioid adenocarcinoma) 
increased from 12,536 to 22,888, whereas that of type II 
endometrial cancers (serous carcinoma and clear cell carci-
noma) was relatively stable, from 1751 to 2169.9 The authors 
suggested that the trends in hormone replacement therapy use 
and the rise of obesity in the US have contributed to the inci-
dence of endometrial cancer, especially among the specific 
histological subtypes. From a UK population-based registry 
from 1994 to 2006, the analyses of endometrial cancer types 
also showed an increase in endometrial cancer incidence that 
was confined to type I cancers (age-standardized incidence 
rate from 12.0 per 100,000 in 1994 to 16.3 per 10,000 in 
2006, P , 0.001), seen most frequently in the 60–79 year age 
groups, while the incidence of type II cancer remained static 
(age-standardized incidence rate from 2.5 per 100,000 in 
1994 to 2.2 per 10,000 in 2006, not significant).10 The 5-year 
relative survival rate in patients with type I cancer improved 
(not significant, P = 0.95), but that of patients with type II 
cancer decreased significantly (P = 0.001). The authors com-
pared the increased incidence of type I cancer to an increase 
in obesity in the UK population and found the relationship 
between endometrial cancer incidence and obesity to be 
complex.
Ueda et al2 showed that the increase in mortality in 
patients with endometrial cancer was related to an increased 
rate of the detection of advanced-stage cancers. However, 
the distributions of the surgical stage were not significantly 
different between the decade A group and the decade B group 
in the present study. The cancer-specific survival rates of 
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Figure 1 Kaplan–Meier analysis of cancer-specific survival stratified by decade.
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the decade A group and the decade B group also showed no 
significant differences. Although the patients in the decade B 
group were more often treated with para-aortic lymph node 
sampling than those in the decade A group, there were no 
significant differences in the incidence of the retroperitoneal 
lymph node metastasis between the decade A group and the 
decade B group. The increased rate of para-aortic lymph 
node sampling influenced the increased number of patients 
with both pelvic and para-aortic lymph node metastases but 
did not influence the rate of adjuvant chemotherapy. Several 
studies have shown the benefits of adjuvant chemotherapy for 
the treatment of early-stage type II endometrial cancer.11,12 
However, the median of survival in the decade B group was 
too short to evaluate the impact of adjuvant chemotherapy 
on the survival of patients with endometrial cancer.
Only one tumor was diagnosed as an endometrioid 
adenocarcinoma by the immunohistochemical findings in the 
present study. The immnohistochemical analysis therefore 
assured the accuracy of the histological typing of endometrial 
cancer in the present study.
Conclusion
There has been an increase in the incidence of serous 
carcinoma, clear cell carcinoma, and carcinosarcoma in 
Japanese patients with endometrial cancer. The increase in 
the proportion of elderly females in the total population is 
probably related to the increase in the diagnosis of high-risk 
endometrial cancers in Japan. The present study is limited 
by a small sample-sized institution-based study. A large 
Japanese population-based study is required.
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